Brief Title: GLORIA-AF Registry Program
Official Title: GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)
NCT Government ID: NCT01468701
Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention
Patients who have received more than 60 days of vitamin K antagonist (VKA) treatment in their lifetime
AF with a generally reversible cause;
Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (for example, a VKA) is indicated
What is the purpose of this study?
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.
Lead Sponsor: Duke University
Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
Technical Information: http://clinicaltrials.gov/ct2/show/NCT00786474
Condition Name: Arterial Thromboembolic Events, Atrial Fibrillation